arrow
C

Curdin Conrad

university hospital lausanne
H指数:44
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of disease duration, bio-naivety, MoA and BMI in predicting PASI 100 under biologic therapy

疾病持续时间、生物素性、作用机制和BMI在预测生物制剂治疗下PASI 100中的作用

2026-10-130
PRE
Early intervention with secukinumab prevents epigenetic scar development in new-onset psoriasis – STEPIn Mechanistic Sub-study results

使用司库奇尤单抗的早期干预可预防新发银屑病中表观遗传疤痕的形成——STEPIn机制性子研究结果

2026-05-250
OAAI
Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA

Secukinumab在斑块状银屑病中的持续疗效、有效性和安全性:SERENA研究5年结果

2026-04-020
OAAI
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

奈莫珠单抗治疗结节性痒疹长达100周: 奥林匹亚LTE中期分析

2025-12-010
OAAI
Enhanced TLR7-dependent production of type I interferon by pDCs underlies pandemic chilblains

pDCs增强的TLR7依赖性I型干扰素产生是导致大流行性冻疮的基础

2025-04-140
OA
The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis

LL37自身抗原的翻译后修饰的性质影响银屑病中自身反应性Th细胞的表型

2025-04-090
OA
Sex Disparities of Health-related Quality of Life in Moderate to Severe Psoriasis: A Real-world Analysis from the Swiss Psoriasis Registry (SDNTT)

中度至重度银屑病患者健康相关生活质量的性别差异: 来自瑞士银屑病登记处 (SDNTT) 的真实世界分析

2025-02-060
OAAI
Immune modules to guide diagnosis and personalized treatment of inflammatory skin diseases
2024-12-180
OAAI
ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis
2024-10-240
OA